Advertisement

Sphingomyelin and Its Role in Cellular Signaling

  • Mahua Chakraborty
  • Xian-Cheng JiangEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 991)

Abstract

Sphingolipid de novo biosynthesis is related with metabolic diseases. However, the mechanism is still not quite clear. Sphingolipids are ubiquitous and critical components of biological membranes. Their biosynthesis starts with soluble precursors in the endoplasmic reticulum and culminates in the Golgi complex and plasma membrane. The interaction of sphingomyelin, cholesterol, and glycosphingolipid drives the formation of plasma membrane rafts. Lipid rafts have been shown to be involved in cell ­signaling, lipid and protein sorting, and membrane trafficking. It is well known that toll-like receptors, class A and B scavenger receptors, and insulin receptor are located in lipid rafts. Sphingomyelin is also a reservoir for other sphingolipids. So, sphingomyelin has important impact in cell ­signaling through its structural role in lipid rafts or its catabolic inter-mediators, such as ceramide and glycoceramide. In this chapter, we will discuss both aspects.

Keywords

Sphingomyelin Ceramide Diacylglycerol Sphingolipids Sphingolipid biosynthesis Lipid rafts Cholesterol homeostasis 

References

  1. 1.
    Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9:139–150PubMedGoogle Scholar
  2. 2.
    Kleger A, Liebau S, Lin Q, von Wichert G, Seufferlein T (2011) The impact of bioactive lipids on cardiovascular development. Stem Cells Int 2011:916180PubMedGoogle Scholar
  3. 3.
    Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387:569–572PubMedGoogle Scholar
  4. 4.
    Li Z, Hailemariam TK, Zhou H, Li Y, Duckworth DC et al (2007) Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. Biochim Biophys Acta 1771:1186–1194PubMedGoogle Scholar
  5. 5.
    Shaul PW, Anderson RG (1998) Role of plasmalemmal caveolae in signal transduction. Am J Physiol 275:L843–L851PubMedGoogle Scholar
  6. 6.
    Futerman AH, Hannun YA (2004) The complex life of simple sphingolipids. EMBO Rep 5:777–782PubMedGoogle Scholar
  7. 7.
    Holthuis JC, van Meer G, Huitema K (2003) Lipid microdomains, lipid translocation and the organization of intracellular membrane transport (Review). Mol Membr Biol 20:231–241PubMedGoogle Scholar
  8. 8.
    Calhoun WI, Shipley GG (1979) Fatty acid composition and thermal behavior of natural sphingomyelins. Biochim Biophys Acta 555:436–441PubMedGoogle Scholar
  9. 9.
    Kolesnick RN (1991) Sphingomyelin and derivatives as cellular signals. Prog Lipid Res 30:1–38PubMedGoogle Scholar
  10. 10.
    Tafesse FG, Ternes P, Holthuis JC (2006) The multigenic sphingomyelin synthase family. J Biol Chem 281:29421–29425PubMedGoogle Scholar
  11. 11.
    Hojjati MR, Jiang XC (2006) Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. J Lipid Res 47:673–676PubMedGoogle Scholar
  12. 12.
    Ishitsuka R, Yamaji-Hasegawa A, Makino A, Hirabayashi Y, Kobayashi T (2004) A lipid-specific toxin reveals heterogeneity of sphingomyelin-­containing membranes. Biophys J 86:296–307PubMedGoogle Scholar
  13. 13.
    Liu J, Zhang H, Li Z, Hailemariam TK, Chakraborty M et al (2009) Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice. Arterioscler Thromb Vasc Biol 29:850–856PubMedGoogle Scholar
  14. 14.
    Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC (2004) Identification of a family of animal sphingomyelin synthases. EMBO J 23:33–44PubMedGoogle Scholar
  15. 15.
    Yamaoka S, Miyaji M, Kitano T, Umehara H, Okazaki T (2004) Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells. J Biol Chem 279:18688–18693PubMedGoogle Scholar
  16. 16.
    Okazaki T, Bell RM, Hannun YA (1989) Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J Biol Chem 264:19076–19080PubMedGoogle Scholar
  17. 17.
    Kim MY, Linardic C, Obeid L, Hannun Y (1991) Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem 266:484–489PubMedGoogle Scholar
  18. 18.
    Dressler KA, Mathias S, Kolesnick RN (1992) Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. Science 255:1715–1718PubMedGoogle Scholar
  19. 19.
    Ballou LR, Chao CP, Holness MA, Barker SC, Raghow R (1992) Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 267:20044–20050PubMedGoogle Scholar
  20. 20.
    Mathias S, Younes A, Kan CC, Orlow I, Joseph C et al (1993) Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science 259:519–522PubMedGoogle Scholar
  21. 21.
    Marchesini N, Hannun YA (2004) Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82:27–44PubMedGoogle Scholar
  22. 22.
    Zeidan YH, Hannun YA (2010) The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. Curr Mol Med 10:454–466PubMedGoogle Scholar
  23. 23.
    Clarke CJ, Wu BX, Hannun YA (2011) The neutral sphingomyelinase family: identifying biochemical connections. Adv Enzyme Regul 51:51–58PubMedGoogle Scholar
  24. 24.
    Duan RD (2006) Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim Biophys Acta 1761:281–291PubMedGoogle Scholar
  25. 25.
    Hannun YA, Obeid LM (2011) Many ceramides. J Biol Chem 286:27855–27862PubMedGoogle Scholar
  26. 26.
    Becker KP, Hannun YA (2005) Protein kinase C and phospholipase D: intimate interactions in intracellular signaling. Cell Mol Life Sci 62:1448–1461PubMedGoogle Scholar
  27. 27.
    Goni FM, Alonso A (1999) Structure and functional properties of diacylglycerols in membranes. Prog Lipid Res 38:1–48PubMedGoogle Scholar
  28. 28.
    Liu WS, Heckman CA (1998) The sevenfold way of PKC regulation. Cell Signal 10:529–542PubMedGoogle Scholar
  29. 29.
    Quest AF, Ghosh S, Xie WQ, Bell RM (1997) DAG second messengers: molecular switches and growth control. Adv Exp Med Biol 400A:297–303PubMedGoogle Scholar
  30. 30.
    Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607–614PubMedGoogle Scholar
  31. 31.
    Brown DA, London E (2000) Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 275:17221–17224PubMedGoogle Scholar
  32. 32.
    Simons K, Toomre D (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31–39PubMedGoogle Scholar
  33. 33.
    Sonnino S, Prinetti A, Nakayama H, Yangida M, Ogawa H et al (2009) Role of very long fatty acid-containing glycosphingolipids in membrane organization and cell signaling: the model of lactosylceramide in neutrophils. Glycoconj J 26:615–621PubMedGoogle Scholar
  34. 34.
    Sonnino S, Prinetti A (2010) Lipids and membrane lateral organization. Front Physiol 1:153PubMedGoogle Scholar
  35. 35.
    Brown RE (1998) Sphingolipid organization in biomembranes: what physical studies of model membranes reveal. J Cell Sci 111(Pt 1):1–9PubMedGoogle Scholar
  36. 36.
    London E, Brown DA (2000) Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 1508:182–195PubMedGoogle Scholar
  37. 37.
    Li XM, Momsen MM, Smaby JM, Brockman HL, Brown RE (2001) Cholesterol decreases the interfacial elasticity and detergent solubility of sphingomyelins. Biochemistry 40:5954–5963PubMedGoogle Scholar
  38. 38.
    Sankaram MB, Thompson TE (1990) Modulation of phospholipid acyl chain order by cholesterol. A solid-state 2H nuclear magnetic resonance study. Biochemistry 29:10676–10684PubMedGoogle Scholar
  39. 39.
    Bittman R, Kasireddy CR, Mattjus P, Slotte JP (1994) Interaction of cholesterol with sphingomyelin in monolayers and vesicles. Biochemistry 33:11776–11781PubMedGoogle Scholar
  40. 40.
    Veiga MP, Arrondo JL, Goni FM, Alonso A, Marsh D (2001) Interaction of cholesterol with sphingomyelin in mixed membranes containing phosphatidylcholine, studied by spin-label ESR and IR spectroscopies. A possible stabilization of gel-phase sphingolipid domains by cholesterol. Biochemistry 40:2614–2622PubMedGoogle Scholar
  41. 41.
    Slotte JP (1997) Cholesterol-sphingomyelin interactions in cells–effects on lipid metabolism. Subcell Biochem 28:277–293PubMedGoogle Scholar
  42. 42.
    Ridgway ND (2000) Interactions between metabolism and intracellular distribution of cholesterol and sphingomyelin. Biochim Biophys Acta 1484:129–141PubMedGoogle Scholar
  43. 43.
    Kan CC, Ruan ZS, Bittman R (1991) Interaction of cholesterol with sphingomyelin in bilayer membranes: evidence that the hydroxy group of sphingomyelin does not modulate the rate of cholesterol exchange between vesicles. Biochemistry 30:7759–7766PubMedGoogle Scholar
  44. 44.
    Masserini M, Ravasi D (2001) Role of sphingolipids in the biogenesis of membrane domains. Biochim Biophys Acta 1532:149–161PubMedGoogle Scholar
  45. 45.
    Schroeder R, London E, Brown D (1994) Interactions between saturated acyl chains confer detergent resistance on lipids and glycosylphosphatidylinositol (GPI)-anchored proteins: GPI-anchored proteins in liposomes and cells show similar behavior. Proc Natl Acad Sci U S A 91:12130–12134PubMedGoogle Scholar
  46. 46.
    Simons K, Ikonen E (2000) How cells handle cholesterol. Science 290:1721–1726PubMedGoogle Scholar
  47. 47.
    Wolf C, Koumanov K, Tenchov B, Quinn PJ (2001) Cholesterol favors phase separation of sphingomyelin. Biophys Chem 89:163–172PubMedGoogle Scholar
  48. 48.
    Galbiati F, Razani B, Lisanti MP (2001) Emerging themes in lipid rafts and caveolae. Cell 106:403–411PubMedGoogle Scholar
  49. 49.
    Pike LJ (2005) Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 1746:260–273PubMedGoogle Scholar
  50. 50.
    Mishra S, Joshi PG (2007) Lipid raft heterogeneity: an enigma. J Neurochem 103(Suppl 1):135–142PubMedGoogle Scholar
  51. 51.
    Patra SK (2008) Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 1785:182–206PubMedGoogle Scholar
  52. 52.
    Tsutsumi YM, Horikawa YT, Jennings MM, Kidd MW, Niesman IR et al (2008) Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 118:1979–1988PubMedGoogle Scholar
  53. 53.
    Minshall RD, Malik AB (2006) Transport across the endothelium: regulation of endothelial permeability. Handb Exp Pharmacol 176:107–144PubMedGoogle Scholar
  54. 54.
    Mukherjee S, Tessema M, Wandinger-Ness A (2006) Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res 98:743–756PubMedGoogle Scholar
  55. 55.
    Nichols B (2003) Caveosomes and endocytosis of lipid rafts. J Cell Sci 116:4707–4714PubMedGoogle Scholar
  56. 56.
    Frick M, Bright NA, Riento K, Bray A, Merrified C et al (2007) Coassembly of flotillins induces formation of membrane microdomains, membrane curvature, and vesicle budding. Curr Biol 17:1151–1156PubMedGoogle Scholar
  57. 57.
    Tahir SA, Yang G, Ebara S, Timme TL, Satoh T et al (2001) Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61:3882–3885PubMedGoogle Scholar
  58. 58.
    Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K et al (2008) Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 68:731–739PubMedGoogle Scholar
  59. 59.
    Williams TM, Lisanti MP (2004) The caveolin proteins. Genome Biol 5:214PubMedGoogle Scholar
  60. 60.
    Dietzen DJ, Hastings WR, Lublin DM (1995) Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. J Biol Chem 270:6838–6842PubMedGoogle Scholar
  61. 61.
    Li S, Seitz R, Lisanti MP (1996) Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem 271:3863–3868PubMedGoogle Scholar
  62. 62.
    Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S et al (2003) Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A 100:3445–3449PubMedGoogle Scholar
  63. 63.
    Kabayama K, Sato T, Saito K, Loberto N, Prinetti A et al (2007) Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci U S A 104:13678–13683PubMedGoogle Scholar
  64. 64.
    Mitsutake S, Zama K, Yokota H, Yoshida T, Tanaka M et al (2011) Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. J Biol Chem 286:28544–28555PubMedGoogle Scholar
  65. 65.
    Li Z, Zhang H, Liu J, Liang CP, Li Y et al (2011) Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol Cell Biol 31:4205–4218PubMedGoogle Scholar
  66. 66.
    Beutler B, Jiang Z, Georgel P, Crozat K, Croker B et al (2006) Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol 24:353–389PubMedGoogle Scholar
  67. 67.
    Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17:1–14PubMedGoogle Scholar
  68. 68.
    Lee HK, Dunzendorfer S, Soldau K, Tobias PS (2006) Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 24:153–163PubMedGoogle Scholar
  69. 69.
    Wang R, Town T, Gokarn V, Flavell RA, Chandawarkar RY (2006) HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated TLR-7 and upregulating p38 MAPK and PI3K pathways. J Surg Res 136:58–69PubMedGoogle Scholar
  70. 70.
    Nakahira K, Kim HP, Geng XH, Nakao A, Wang X et al (2006) Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med 203:2377–2389PubMedGoogle Scholar
  71. 71.
    Szabo G, Dolganiuc A, Dai Q, Pruett SB (2007) TLR4, ethanol, and lipid rafts: a new mechanism of ethanol action with implications for other receptor-mediated effects. J Immunol 178:1243–1249PubMedGoogle Scholar
  72. 72.
    Miggin SM, O’Neill LA (2006) New insights into the regulation of TLR signaling. J Leukoc Biol 80:220–226PubMedGoogle Scholar
  73. 73.
    Miyake K (2006) Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 12:195–204PubMedGoogle Scholar
  74. 74.
    Triantafilou M, Brandenburg K, Kusumoto S, Fukase K, Mackie A et al (2004) Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem J 381:527–536PubMedGoogle Scholar
  75. 75.
    Triantafilou M, Morath S, Mackie A, Hartung T, Triantafilou K (2004) Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane. J Cell Sci 117:4007–4014PubMedGoogle Scholar
  76. 76.
    Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C (2003) Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 18:655–664PubMedGoogle Scholar
  77. 77.
    Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45–65PubMedGoogle Scholar
  78. 78.
    Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296:1634–1635PubMedGoogle Scholar
  79. 79.
    Luberto C, Yoo DS, Suidan HS, Bartoli GM, Hannun YA (2000) Differential effects of sphingomyelin hydrolysis and resynthesis on the activation of NF-kappa B in normal and SV40-transformed human fibroblasts. J Biol Chem 275:14760–14766PubMedGoogle Scholar
  80. 80.
    Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K et al (1992) TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced “acidic” sphingomyelin breakdown. Cell 71:765–776PubMedGoogle Scholar
  81. 81.
    Hailemariam TK, Huan C, Liu J, Li Z, Roman C et al (2008) Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol 28:1519–1526PubMedGoogle Scholar
  82. 82.
    Li Z, Fan Y, Liu J, Li Y, Huan C et al (2012) Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32:1577–1584PubMedGoogle Scholar
  83. 83.
    Merrill AH Jr, Jones DD (1990) An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta 1044:1–12PubMedGoogle Scholar
  84. 84.
    Yamaji-Hasegawa A, Makino A, Baba T, Senoh Y, Kimura-Suda H et al (2003) Oligomerization and pore formation of a sphingomyelin-specific toxin, lysenin. J Biol Chem 278:22762–22770PubMedGoogle Scholar
  85. 85.
    Tall AR (1998) An overview of reverse cholesterol transport. Eur Heart J 19(Suppl A):A31–A35PubMedGoogle Scholar
  86. 86.
    Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809PubMedGoogle Scholar
  87. 87.
    Freeman M, Ashkenas J, Rees DJ, Kingsley DM, Copeland NG et al (1990) An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc Natl Acad Sci U S A 87:8810–8814PubMedGoogle Scholar
  88. 88.
    Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P et al (1990) Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 343:531–535PubMedGoogle Scholar
  89. 89.
    Cavelier C, Lorenzi I, Rohrer L, von Eckardstein A (2006) Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 1761:655–666PubMedGoogle Scholar
  90. 90.
    Jessup W, Gelissen IC, Gaus K, Kritharides L (2006) Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 17:247–257PubMedGoogle Scholar
  91. 91.
    Gaus K, Kritharides L, Schmitz G, Boettcher A, Drobnik W et al (2004) Apolipoprotein A-1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages. FASEB J 18:574–576PubMedGoogle Scholar
  92. 92.
    Mendez AJ, Lin G, Wade DP, Lawn RM, Oram JF (2001) Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. J Biol Chem 276:3158–3166PubMedGoogle Scholar
  93. 93.
    Wang N, Ranalletta M, Matsuura F, Peng F, Tall AR (2006) LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 26:1310–1316PubMedGoogle Scholar
  94. 94.
    Huang ZH, Gu D, Lange Y, Mazzone T (2003) Expression of scavenger receptor BI facilitates sterol movement between the plasma membrane and the endoplasmic reticulum in macrophages. Biochemistry 42:3949–3955PubMedGoogle Scholar
  95. 95.
    Graf GA, Connell PM, van der Westhuyzen DR, Smart EJ (1999) The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J Biol Chem 274:12043–12048PubMedGoogle Scholar
  96. 96.
    Babitt J, Trigatti B, Rigotti A, Smart EJ, Anderson RG et al (1997) Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 272:13242–13249PubMedGoogle Scholar
  97. 97.
    Landry YD, Denis M, Nandi S, Bell S, Vaughan AM et al (2006) ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 281:36091–36101PubMedGoogle Scholar
  98. 98.
    Leventhal AR, Chen W, Tall AR, Tabas I (2001) Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 276:44976–44983PubMedGoogle Scholar
  99. 99.
    Nagao K, Takahashi K, Hanada K, Kioka N, Matsuo M et al (2007) Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient Chinese hamster ovary cells. J Biol Chem 282:14868–14874PubMedGoogle Scholar
  100. 100.
    Liu J, Huan C, Chakraborty M, Zhang H, Lu D et al (2009) Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ Res 105:295–303PubMedGoogle Scholar
  101. 101.
    Fessler MB, Parks JS (2011) Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol 187:1529–1535PubMedGoogle Scholar
  102. 102.
    Peshavariya H, Dusting GJ, Di Bartolo B, Rye KA, Barter PJ et al (2009) Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic Res 43:772–782PubMedGoogle Scholar
  103. 103.
    Fielding PE, Russel JS, Spencer TA, Hakamata H, Nagao K et al (2002) Sterol efflux to apolipoprotein A-I originates from caveolin-rich microdomains and potentiates PDGF-dependent protein kinase activity. Biochemistry 41:4929–4937PubMedGoogle Scholar
  104. 104.
    Slotte JP (1999) Sphingomyelin-cholesterol interactions in biological and model membranes. Chem Phys Lipids 102:13–27PubMedGoogle Scholar
  105. 105.
    Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M et al (2008) Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 118:1837–1847PubMedGoogle Scholar
  106. 106.
    Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL et al (2010) Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res 51:3196–3206PubMedGoogle Scholar
  107. 107.
    Frisdal E, Lesnik P, Olivier M, Robillard P, Chapman MJ et al (2011) Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the pro-inflammatory response. J Biol Chem 286:30926–30936PubMedGoogle Scholar
  108. 108.
    Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM et al (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5:167–179PubMedGoogle Scholar
  109. 109.
    Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS et al (2004) Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 110:3465–3471PubMedGoogle Scholar
  110. 110.
    Hojjati MR, Li Z, Zhou H, Tang S, Huan C et al (2005) Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 280:10284–10289PubMedGoogle Scholar
  111. 111.
    Glaros EN, Kim WS, Wu BJ, Suarna C, Quinn CM et al (2007) Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol 73:1340–1346PubMedGoogle Scholar
  112. 112.
    Stratford S, DeWald DB, Summers SA (2001) Ceramide dissociates 3′-phosphoinositide production from pleckstrin homology domain translocation. Biochem J 354:359–368PubMedGoogle Scholar
  113. 113.
    Powell DJ, Hajduch E, Kular G, Hundal HS (2003) Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 23:7794–7808PubMedGoogle Scholar
  114. 114.
    Blouin CM, Prado C, Takane KK, Lasnier F, Garcia-Ocana A et al (2010) Plasma membrane subdomain compartmentalization contributes to distinct mechanisms of ceramide action on insulin signaling. Diabetes 59:600–610PubMedGoogle Scholar
  115. 115.
    Holland WL, Summers SA (2008) Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 29:381–402PubMedGoogle Scholar
  116. 116.
    de Mello VD, Lankinen M, Schwab U, Kolehmainen M, Lehto S et al (2009) Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52:2612–2615PubMedGoogle Scholar
  117. 117.
    Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C et al (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56:1210–1218PubMedGoogle Scholar
  118. 118.
    Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M et al (2007) Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56:1341–1349PubMedGoogle Scholar
  119. 119.
    Gorska M, Dobrzyn A, Zendzian-Piotrowska M, Gorski J (2004) Effect of streptozotocin-diabetes on the functioning of the sphingomyelin-signalling pathway in skeletal muscles of the rat. Horm Metab Res 36:14–21PubMedGoogle Scholar
  120. 120.
    Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Kinalska I et al (2004) Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 53:1215–1221PubMedGoogle Scholar
  121. 121.
    Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA et al (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25–31PubMedGoogle Scholar
  122. 122.
    Turinsky J, O’Sullivan DM, Bayly BP (1990) 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 265:16880–16885PubMedGoogle Scholar
  123. 123.
    Skovbro M, Baranowski M, Skov-Jensen C, Flint A, Dela F et al (2008) Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 51:1253–1260PubMedGoogle Scholar
  124. 124.
    Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806PubMedGoogle Scholar
  125. 125.
    Virkamaki A, Ueki K, Kahn CR (1999) Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931–943PubMedGoogle Scholar
  126. 126.
    Parpal S, Karlsson M, Thorn H, Stralfors P (2001) Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J Biol Chem 276:9670–9678PubMedGoogle Scholar
  127. 127.
    Langeveld M, Aerts JM (2009) Glycosphingolipids and insulin resistance. Prog Lipid Res 48:196–205PubMedGoogle Scholar
  128. 128.
    Chakraborty M, Lou C, Huan C, Kuo M, Park, T, Cao, G, Jiang XC (2013) Myeloid cell-specific serine palmitoyltransferase subunit 2 haploinsuffi­ciency reduces mouse atherosclerosis. J Clin Invest. doi: 10.1172/JC16041S

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Cell BiologySUNY Downstate Medical CenterBrooklynUSA
  2. 2.Molecular and Cellular Cardiology ProgramVA New York Harbor Healthcare SystemBrooklynUSA

Personalised recommendations